Differential expression of murine macrophage surface glycoprotein antigens in intracellular membranes

A monoclonal antibody recognizing a novel murine macrophage glycoprotein antigen (MAG) was prepared by the hybridoma technique. Using live and permeabilized macrophages to estimate surface and total MAG, respectively, it was found that at least 50% of the total antigen was intracellular. In contrast, another macrophage surface glycoprotein antigen, Mac-1, was undetectable in the intracellular pool. Immunofluorescence studies confirmed the existence of a substantial intracellular pool of MAG antigen. Similar results were obtained with a panel of cultured tumour cell lines. In one such cell line, it was shown that surface MAG existed in a distinct punctate pattern indicative of microdomains, whereas surface Mac-1 antigen gave a uniform distribution. The possible role of the surface microdomains in the differential expression of the two surface glycoproteins in intracellular membranes is discussed.

Download Full-text

Faculty Opinions recommendation of Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.11512.467521 ◽

2006 ◽

Author(s):

Helena Tlaskalova-Hogenova

Keyword(s):

Gene Expression ◽

Immune Response ◽

Celiac Disease ◽

Intestinal Permeability ◽

Innate Immune Response ◽

Innate Immune ◽

Murine Macrophage ◽

Inflammatory Gene Expression ◽

Stimulation Of

Download Full-text

Differential expression and role of p21cip/waf1 and p27kip1 in TNF-α-induced inhibition of proliferation in human glioma cells

Molecular Cancer ◽

10.1186/1476-4598-6-42 ◽

2007 ◽

Vol 6 (1) ◽

pp. 42 ◽

Cited By ~ 17

Author(s):

Pabbisetty Kumar ◽

Anjali Shiras ◽

Gowry Das ◽

Jayashree C Jagtap ◽

Vandna Prasad ◽

...

Keyword(s):

Differential Expression ◽

Glioma Cells ◽

Human Glioma ◽

Human Glioma Cells ◽

Inhibition Of Proliferation ◽

Tnf Α

Download Full-text

Role of CA 19-9 in complex ovarian tumors

10.1055/s-0039-1685299 ◽

2016 ◽

Author(s):

Dhanya S. Thomas ◽

Ajit Sebastian ◽

Vinotha Thomas ◽

Anitha Thomas ◽

Rachel Chandy ◽

...

Keyword(s):

Malignant Tumors ◽

Ovarian Tumors ◽

Benign Tumors ◽

Ovarian Mass ◽

Radiological Findings ◽

Epithelial Tumors ◽

Mucin Glycoprotein ◽

Glycoprotein Antigen ◽

Mucinous Tumours

Background: Cancer antigen 19-9 (CA 19-9) is a tumor-associated mucin glycoprotein antigen that may be elevated in healthy individuals as well as in patients with benign and malignant tumors. It is useful in the management of pancreatic and other gastrointestinal tumors. CA 19-9 is also elevated in benign and malignant ovarian tumors. Aim: To study the pattern of serum CA19-9 in complex ovarian tumors. Methods: The study design was descriptive, based on data collected from medical records. Patients with a complex ovarian mass, who were investigated with CA 19-9 and had undergone surgery, wereincluded in the study. The study duration was 2 years from January 2014 to December 2015. A total of 273 patients (119 - benign and 154 malignant) with complex ovarian mass and elevated CA 19-9 underwent surgery during the study period. Results: CA 19-9 was elevated in 55 patients (20%). Of these, 23 patients had benign tumors while 32 had malignant tumors.Among patients with benign tumors, 21 had dermoid, 23 had mucinous tumors and 75 had other types of tumors. CA 19-9 was elevated in 10 (47.6%) of the dermoids, 7 (30.4%) of the mucinous tumors and 6 (8%) of the other benign tumors. Among patients with malignant tumors, 138 were epithelial and 16 were non epithelial tumors. Of the epithelial tumors, 31 were mucinous and 107 were non mucinous types. Overall, 29 (21%) had elevated CA 19-9. Of the epithelial tumors, 22.6% of the mucinous type and 20.6% of the non mucinous type had elevated CA 19-9. Among the non-epithelial tumors, 3 (18.8%) had elevated CA19-9. Conclusion: CA 19-9 is elevated in several conditions but most likely to be raised in dermoid cysts and mucinous tumours. CA19-9 levels need to be interpreted along with clinical and radiological findings.

Download Full-text

Differential expression of triiodothyronine receptors in schwannoma and neurofibroma: role of Schwann cell-axon interaction

Acta Neuropathologica ◽

10.1007/bf00294313 ◽

1995 ◽

Vol 90 (2) ◽

pp. 142-149 ◽

Cited By ~ 2

Author(s):

I. Barakat Walter ◽

J. P. Deruaz ◽

N. de Tribolet

Keyword(s):

Schwann Cell ◽

Differential Expression ◽

Cell Axon

Download Full-text

Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells.

The Journal of Cell Biology ◽

10.1083/jcb.105.2.983 ◽

1987 ◽

Vol 105 (2) ◽

pp. 983-990 ◽

Cited By ~ 343

Author(s):

S Jalkanen ◽

R F Bargatze ◽

J de los Toyos ◽

E C Butcher

Keyword(s):

Monoclonal Antibody ◽

Lymph Node ◽

Human Lymphocyte ◽

Molecular Mechanisms ◽

Polyclonal Antiserum ◽

Surface Glycoprotein ◽

Lymphoid Tissues ◽

Specific Cell ◽

High Endothelial Venules ◽

Glycoprotein Antigen

The tissue-specific homing of lymphocytes is directed by specialized high endothelial venules (HEV). At least three functionally independent lymphocyte/HEV recognition systems exist, controlling the extravasation of circulating lymphocytes into peripheral lymph nodes, mucosal lymphoid tissues (Peyer's patches or appendix), and the synovium of inflamed joints. We report here that antibodies capable of inhibiting human lymphocyte binding to one or more HEV types recognize a common 85-95-kD lymphocyte surface glycoprotein antigen, defined by the non-blocking monoclonal antibody, Hermes-1. We demonstrate that MEL-14, a monoclonal antibody against putative lymph node "homing receptors" in the mouse, functionally inhibits human lymphocyte binding to lymph node HEV but not to mucosal or synovial HEV, and cross-reacts with the 85-95-kD Hermes-1 antigen. Furthermore, we show that Hermes-3, a novel antibody produced by immunization with Hermes-1 antigen isolated from a mucosal HEV-specific cell line, selectively blocks lymphocyte binding to mucosal HEV. Such tissue specificity of inhibition suggests that MEL-14 and Hermes-3 block the function of specific lymphocyte recognition elements for lymph node and mucosal HEV, respectively. Recognition of synovial HEV also involves the 85-95-kD Hermes-1 antigen, in that a polyclonal antiserum produced against the isolated antigen blocks all three classes of lymphocyte-HEV interaction. From these studies, it is likely that the Hermes-1-defined 85-95-kD glycoprotein class either comprises a family of related but functionally independent receptors for HEV, or associates both physically and functionally with such receptors. The findings imply that related molecular mechanisms are involved in several functionally independent cell-cell recognition events that direct lymphocyte traffic.

Download Full-text